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AbstrACt
Objectives To explore: (1) the views of Australian 
physiotherapists regarding potential implementation 
of non-medical prescribing in Australia, (2) how the 
geographical location and health sector in which a 
clinician works may influence their perceptions and (3) 
the perceptions of Australian physiotherapists about how 
physiotherapist prescribing might impact the care that the 
profession can provide.
Design A cross-sectional descriptive survey using open 
and closed questions.
setting Participants completed an online questionnaire.
Participants 883 Australian Health Professionals 
Registration Authority (AHPRA)-registered physiotherapists, 
working across all states and territories.
Outcome measures An online questionnaire was 
developed by a panel of subject experts and pretested 
(n=10) for internal consistency. A hyperlink to the 
questionnaire was emailed to all members of the 
Australian Physiotherapy Association. A reminder email 
was sent 4 weeks later. Quantitative data were analysed 
descriptively, with use of absolute risk reductions (ARRs) 
and 95% CIs to determine the likelihood that health 
sector or geographical location were associated with 
specific views. Thematic analysis enabled synthesis of the 
qualitative data.
results 79.0% participants felt that physiotherapist 
prescribing should be introduced in Australia, with 71.2% 
wanting to train as prescribers. Clinical governance, risk 
management, regulation of clinicians and the development 
of an education framework were identified as priorities 
for implementation. Participants working in the private 
sector were significantly more likely to train as prescribers 
than those in the public sector (ARR 9.9%; 95% CI 3.5 to 
16.4) or educational/research institutions (ARR 23.3%; 
95% CI 12.8 to 33.8), with city dwellers significantly more 
likely to train compared with physiotherapists in remote 
regions (ARR 19.8%; 95% CI 0.8 to 39.2). Physiotherapist 
prescribing was predicted to improve efficiency of 
healthcare delivery, access to medicines and reductions in 
healthcare costs.
Conclusions AHPRA-registered physiotherapists perceive 
that the introduction of autonomous physiotherapist 
prescribing would be beneficial for the Australian 
population and should be introduced. Decision makers 
should consider the results of this survey in conjunction 
with cost–benefit and risk analysis when planning the 
introduction of physiotherapist prescribing.
bACkgrOunD AnD rAtiOnAle
Non-medical prescribing (NMP) has been 
used in clinical practice by a variety of profes-
sions for over 20 years.1 However, it was not 
until 2012 that in the UK, physiotherapists 
were first granted independent prescribing 
responsibilities. In July 2015, the Australian 
Physiotherapy Association (APA) in collabora-
tion with the Australia Physiotherapy Council 
and Council of Physiotherapy Deans Australia 
and New Zealand submitted a proposal for 
the endorsement of registered physiothera-
pists for autonomous prescribing to the Phys-
iotherapy Board of Australia.2 To prescribe 
medicines autonomously, a practitioner must 
be responsible for the assessment and diag-
nosis of the patient, prescribing drugs from 
a specified formulary within their individual 
scope of practice. The clinician manages 
ongoing therapy without the requirement 
of protocols or supervision.3 Difficulties in 
accessing medicines for Australians living in 
strengths and limitations of this study
 ► First rigorous survey investigating the perceptions 
of Australian physiotherapists about the potential 
implementation of physiotherapist prescribing in 
Australia.
 ► Results provide the evidence required by the phys-
iotherapy professional association, health depart-
ments and political leaders to inform clinically safe 
and economically sound decisions about redefining 
the scope of physiotherapy in Australia to include 
non-medical prescribing.
 ► Limitations are inherent with all survey-based re-
search due to selection and response bias.
 ► It was not possible to determine why non-respond-
ers did not participate.
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rural and remote areas alongside recognised health ineq-
uities between minority groups such as Aboriginal and 
Torres Strait Islander peoples were cited as key drivers 
for reform. Benefits of the implementation of prescribing 
by physiotherapists in Australia, such as the potential 
to increase access to medicines for health service users 
across all communities,2 are therefore anticipated.
The clinical and cost-effectiveness of NMP remains 
unclear, with a recent systematic review finding only 
minimal empirical evidence with unknown risk of bias4; 
nonetheless, its popularity in clinical practice continues 
to grow.5 A contemporary and robust mixed-methods 
systematic review of 50 moderate to good quality studies, 
investigating the barriers to and facilitators of indepen-
dent NMP, identified conflict within a profession as a key 
barrier to successful implementation.5 A united profes-
sional position regarding the adoption of innovative clin-
ical practice was highlighted as essential to ensure the 
development of safe and high-quality practice. Divided 
opinion between individual clinicians, academics and 
professional managers/leaders may lead to confusion 
across the healthcare community, resulting in unwar-
ranted negative thoughts and perceptions about NMP 
roles and responsibilities. Diverse perceptions regarding 
the implementation of physiotherapist prescribing and 
current physiotherapeutic pharmacological knowledge 
and practices have been reported in national evaluations 
in Nigeria, South Africa and the UK.6–9 Data from these 
evaluations have been used to influence national policy 
and the political drive towards or against the adoption of 
NMP within the physiotherapy profession in these coun-
tries.8 9 Acceptance and support for prescribing by the 
Australian physiotherapy profession will be required for 
successful implementation into local and national health 
systems.2 10–12 It is therefore important that the views of 
Australian physiotherapists are understood in order 
to inform key stakeholders and decision makers about 
redefining the scope of physiotherapy to include NMP 
in Australia. To date, no evidence exists evaluating the 
Australian physiotherapy professions’ views and percep-
tions about the potential use of NMP by physiotherapists 
in Australia.
ObjeCtives
1. To explore the views of Australian physiotherapists 
about the potential implementation and use of NMP 
by physiotherapists in Australia.
2. To explore how the geographical location and health 
sector in which a clinician’s works may influence the 
perceptions of Australian physiotherapists about the 
potential implementation and application of NMP by 
physiotherapists in Australia.
3. To explore the perceptions of Australian physiother-
apists about how physiotherapist prescribing might 
impact the care that the physiotherapy profession can 
provide.
MethODs
A detailed study protocol was published to ensure trans-
parency and reproducibility.13 The study is reported in line 
with an adapted version of the Standard Protocol Items: 
Recommendations for Interventional Trials statement,14 
recommended by the SUrvey Reporting GuidelinE.15 This 
article reports the data collected from registered physio-
therapists from a larger study evaluating both registered 
and student physiotherapists in Australia.13 The data 
collected evaluating the views and perceptions of student 
physiotherapists about the implementation of physiother-
apist prescribing in Australia are presented in the related 
article published independently.16
survey design
A cross-sectional online descriptive survey design enabled 
the collection of empirical data across Australia.17–19 
An online questionnaire was developed using Qualtrics 
(Qualtrics, Provo, Utah, USA), thus enabling Austra-
lian-wide participation with no geographical or time zone 
constraints.17 20
Participants
Participant inclusion criteria are described in box 1. 
According to data published by the Physiotherapy Board 
of Australia, 30 004 physiotherapists were registered with 
the Australian Health Professionals Registration Authority 
(AHPRA) at the time of the survey.21
Procedure
AHPRA privacy policy22 prohibits approaching 
AHPRA-registered physiotherapists directly. Therefore, 
an advertisement containing a link to the online survey 
was emailed to all members of the APA, including all 
clinical and professional networks. A reminder advertise-
ment was sent via email 4 weeks after the initial email to 
promote participation in the survey.17 19 20 IP addresses 
were not saved to ensure participant anonymity. The APA 
membership was selected as the recruitment platform as 
it is representative of all physiotherapy specialties and 
levels of experience (qualified and student physiothera-
pists) across Australia, with 23 153 members at the time of 
survey.23 Word-of-mouth referrals to the survey through 
professional networks were promoted in the email to 
facilitate capturing the views of non-APA members.17 19 20 
Data collection took place 1 March–30 April 2017. Partic-
ipants accessed the questionnaire via the online link. 
Completion of the survey was anonymous and entirely 
voluntary.17 19 20 Participant consent was gained using an 
online information and consent form.17–19 Researcher 
contact details were supplied to enable any questions or 
box 1 Participant inclusion criteria
 ► Physiotherapists registered with Australian Health Professionals 
Registration Authority.
 ► Ability to read and understand written English.
 ► Provision of consent to participate in the survey independently.
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concerns to be answered prior to completing the online 
questionnaire.17–19
Questionnaire development
Data from a mixed methods systematic review examining 
the barriers to and facilitators of NMP internationally 
informed the questionnaire design and specific question 
inclusion.5 Questions were optimised through consulta-
tion with experts in the fields of physiotherapy, NMP and 
Australian state/federal law and health policy.17–19
The questionnaire consisted of four sections:
1. Demographic information including participants’ 
age/gender/number of years qualified/specialty/
location.
2. Participants’ perceptions of the positive and/or nega-
tive aspects of physiotherapist prescribing to the pro-
fession as a whole.
3. Participants’ perceptions of the impact of physiothera-
pist prescribing to them as an individual.
4. Participants’ perceptions regarding the potential wid-
er impacts of physiotherapist prescribing.
Sections 1–3 used closed questions to collect quantita-
tive data. Section 4 contained two open-ended questions 
to allow the participants to answer without limitation.17 19 
In-built survey logic ensured that participants were shown 
questions that were pertinent to them based on their 
previous answers. Before completion, participants were 
encouraged to share any additional information that they 
deemed relevant, capturing useful insights not addressed 
elsewhere in the questionnaire.17–19
The questionnaire was piloted to test for internal consis-
tency and optimise user experience.18 Ten participants 
(n=7 registered physiotherapists, n=3 student physiother-
apists) were purposely sampled to represent the physio-
therapy profession in Australia.17–19 Following the pilot, 
Anglo-Australian terminology was clarified, and small 
changes were made to the linguistics and survey logic. 
Pilot participants were not excluded from completing the 
final questionnaire. The final questionnaire can be found 
in online supplementary file 1.
Data storage
All electronic data were stored in password-protected 
computer files only accessible by study investigators. 
Participants who disclosed personal details were addi-
tionally protected via coding on data files.17–19 The pass-
word-protected files will be retained for 10 years, satisfying 
ethical and university policies.
Data analysis
Demographic data (section 1) were tabulated, and 
primary descriptive analysis of the data was completed 
using IBM SPSS Statistics for Macintosh, V.22.0. Compar-
isons of proportions from questions in sections 2 and 3, 
addressing objectives 1 and 2, were conducted using the 
PEDro CI calculator (http://www. pedro. org. au).24 25 
Calculations of absolute risk reductions (ARRs) with 95% 
CIs were used to determine the likelihood that health 
sector or geographical location were associated with 
specific views.25 Thematic analysis was used to ensure 
the transparent synthesis of data addressing objective 3, 
collected in section 4 of the online questionnaire. This 
analysis enabled the identification of key themes within 
a structured analytical framework.26 Answers were coded 
line-by-line using NVivo 11 software (QSR International, 
Melbourne, Australia) by one researcher (TDN) and 
were verified by a second researcher (TJ). Independently 
generated themes/subthemes were then examined by a 
panel of experts for confirmation and agreement.26
Patient and public involvement
The development of this study was informed by the expe-
riences of patients and the general public acknowledged 
in the literature. Due to the study’s objectives, patients 
and the general public were not used in design of the 
study or in participant recruitment. The results will be 
disseminated to all interested parties through publication 
and presentation at professional conferences.
results
Demographics
A total of 883 participants (3% of all AHPRA-regis-
tered physiotherapists) completed the questionnaire. 
Demographic data are presented in table 1. Fifty-eight 
per cent of participants had been qualified for more 
than 10 years, with the majority of participants (88.4%) 
gaining their primary professional qualification in 
Australia. The largest proportion of participants (n=536, 
61%) identified musculoskeletal physiotherapy as their 
specialty area of practice. Of those working clinically, 52% 
of participants worked in the private health sector. There 
were participants from every state and territory, with the 
majority practising in New South Wales (n=299, 34%), 
Victoria (n=234, 27%), Western Australia (n=130, 15%) 
or Queensland (n=115, 13%). Seventy-eight per cent of 
participants worked in a major city.
Participants’ perceptions about the impact of physiotherapist 
prescribing on the physiotherapy profession
Six hundred and eighty participants (79%) reported 
that they strongly agreed or agreed that autonomous 
prescribing responsibilities should be introduced for 
physiotherapists in Australia, with 144 participants (12%) 
against the introduction (figure 1). Potential benefits and 
concerns were identified.
The participants reported that physiotherapist 
prescribing could have a range of benefits in the Austra-
lian healthcare system (figure 1). The most commonly 
identified benefit was an improvement in the delivery of 
health services (80.1%; n=707). Reduced costs of health-
care delivery to the consumer, as well as a reduction in the 
overall cost of healthcare and an improved consumer expe-
rience were also identified as potential benefits of NMP in 
Australia. Participants’ concerns about the prescription of 
medicines by physiotherapists centred on quality and safety 
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issues. In particular, concerns about whether physiothera-
pists have the knowledge required to train as a prescriber 
(34.8%) and a potential increased safety risk to consumers 
(34.1%) were raised. One-third of participants (33.1%) 
were concerned that the expected remuneration for this 
service would not reflect the increased professional risk.
Figure 2 illustrates participants’ opinions about the 
number of years of experience a physiotherapist should 
have prior to being permitted to train as a prescriber. The 
majority of participants felt that physiotherapists should 
have 3 years or more of experience (68.4%), with 34.6% 
believing this should be at least 6 years.
Participants’ perceptions about the impact of physiotherapist 
prescribing to them as an individual
Six hundred and eight participants (71.2%) would be 
extremely likely (n=397, 47%) or somewhat likely (n=211, 
Table 1 Demographic data
AHPRA-
registered 
physiotherapists 
n (%)
Total participants 883 (100)
Gender (n=883 answered)
  Male 366 (41.4)
  Female 517 (58.6)
Age (n=883 answered) (years)
  17–29 258 (29.2)
  30–39 260 (29.4)
  40–49 173 (19.6)
  50–59 124 (14.0)
  60+ 68 (7.7)
Number of years qualified as a 
physiotherapist (n=883 answered)
  0–4 192 (21.7)
  5–9 178 (20.1)
  10–14 109 (12.4)
  15–19 101 (11.5)
  20+ 303 (34.3)
Country of primary qualification 
(n=883 answered)
  Australia 781 (88.4)
  Overseas
  (Belgium, Canada, Germany, Hong 
Kong, India, Ireland, Italy, Mexico, 
Netherlands, New Zealand, Philippines, 
Portugal, Serbia, Singapore, South 
Africa, Taiwan, UK and USA)
102 (11.6)
Predominant physiotherapy practice 
specialties:
(max of 3 specialties identified per 
participant, n=865 answered)
  Amputees 10 (1.1)
  Burns/plastics 9 (1.0)
  Cardiorespiratory 132 (14.9)
  Chronic disease management 100 (11.3)
  Education 58 (6.6)
  Emergency department 65 (7.4)
  Gerontology/aged care 115 (13.0)
  Health promotion/public health 10 (1.1)
  Lymphoedema 11 (1.2)
  Mental health 4 (0.5)
  Musculoskeletal/orthopaedics 536 (60.7)
  Neurology 81 (9.2)
  Occupational health 21 (2.4)
  Paediatrics 37 (4.2)
  Pain 105 (11.9)
Continued
AHPRA-
registered 
physiotherapists 
n (%)
  Palliative care 6 (0.7)
  Rheumatology 10 (1.1)
  Rural generalist 39 (4.4)
  Women’s health/continence 53 (6.0)
  Veterinary 2 (0.2)
Health sector (n=872 answered)
  Public sector 325 (37.3)
  Private sector 449 (51.5)
  Educational/research institute or 
university
49 (5.6)
  Not-for-profit organisation 36 (4.1)
  Other 13 (1.5)
Rural, Remote and Metropolitan Areas 
classification39
(n=783 answered)
  Major cities of Australia 679 (77.8)
  Inner regional Australia 113 (12.9)
  Regional Australia 58 (6.6)
  Remote Australia 20 (2.3)
  Very remote Australia 3 (0.3)
State or territory (n=879 answered)
  Australian Capital Territory 19 (2.2)
  New South Wales 299 (34.0)
  Northern Territory 7 (0.8)
  Queensland 115 (13.1)
  South Australia 64 (7.3)
  Tasmania 11 (1.3)
  Victoria 234 (26.6)
  Western Australia 130 (14.8)
Table 1 Continued 
 o
n
 28 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024991 on 19 May 2019. Downloaded from 
5Noblet TD, et al. BMJ Open 2019;9:e024991. doi:10.1136/bmjopen-2018-024991
Open access
Figure 1 Physiotherapists’ belief as to whether physiotherapist prescribing should be introduced in Australia; potential benefits 
and participants’ concerns.
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25%) to train as a prescriber if this were permitted, while 
174 participants (20.3%) would not. Figure 3 outlines the 
key motivators and deterrents among participants to train 
as a prescriber.
Key motivators cited included the ability to provide 
improved quality of care (n=646, 96.0%) and the 
improved professional reputation associated with NMP 
(n=416, 61.8%). Some participants included increased 
job satisfaction (n=303, 45.0%) and remuneration 
(n=125, 18.6%) as motivating factors. Additionally, some 
participants (n=72, 10.7%) reported being motivated by 
potential clinical and cost efficiencies for both for the 
consumer and healthcare provider through enhanced 
clinical pathways, improved access to medicines and opti-
misation of clinical knowledge.
The most common deterrent for training to be a 
prescriber was the belief that this will not change the care 
that the individual physiotherapist would provide to their 
patients (n=152, 61.8%). Concerns around an increased 
level of clinical responsibility were also highlighted as 
potential deterrents (n=108, 43.9%). Some participants 
felt that they did not have sufficient background knowl-
edge to undertake the prescribing course (n=76, 30.9%). 
Additionally, participants reported that the cost of training 
or distance to travel to universities would be too great 
or that they were nearing retirement and did not want 
the additional stress of training to become a prescriber. 
Furthermore, it is noted that a small number of partici-
pants reported that they would not train as prescribers 
as they are employed in non-clinical roles (n=35, 14.2%).
influence of health sector and geographical location
The percentage of participants from different health 
sectors and geographical locations, who agreed or 
strongly agreed with autonomous prescribing responsibil-
ities being introduced for Australian physiotherapists and 
those who stated that they were extremely likely or some-
what likely to want to train as a prescriber are summarised 
in table 2.
Participants working in the private sector were signifi-
cantly more likely to agree that autonomous prescribing 
responsibilities should be introduced for physiotherapist 
in Australia than those who work in education, not-for-
profit organisations and the military (ARR 9.8%, 95% CI 
0.8 to 20.2). No significant difference (ARR 1.7%; 95% CI 
−4.0 to 7.6) was seen between participants who worked 
in the private or public healthcare sectors. Participants 
working in the private sector were significantly more 
likely to train as prescribers than those working in the 
public sector (ARR 9.9%; 95% CI 3.5 to 16.4) or other 
areas, such as within educational or research institutions 
(ARR 23.3%; 95% CI 12.8 to 33.8). A significantly higher 
proportion of participants in city regions expressed a wish 
to train as a prescriber compared with those in remote 
regions (ARR 19.8%; 95% CI 0.8 to 39.2). Those practising 
in cities (ARR 24.0%, 95% CI 5.8 to 43.9) and regional 
areas (ARR 19.5%, 95% CI 0.4 to 40.1) were significantly 
more likely to agree with the introduction of physio-
therapist prescribing than those from remote regions. 
However, there was no significant difference (ARR 4.4%, 
95% CI −2.2 to 12.0) between participants who practise in 
major cities compared with regional areas.
Wider impacts of physiotherapist prescribing
Participants were asked to provide additional comments 
about how NMP may impact the overall level of care that 
the profession is able to provide. In total, 230 participants 
provided comments.
Figure 2 The number of years’ experience a physiotherapist should have prior to being able to train as a physiotherapist 
prescriber.
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Four major themes were identified:
1. Clinical and cost-efficiency.
2. Access to prescription medicines.
3. Optimal therapeutics and clinical effectiveness.
4. Time management.
Table 3 lists the number of participants that reported or 
discussed each theme and provides illustrative quotations.
Clinical and cost-efficiency
One hundred and eighteen participants commented 
that the introduction of autonomous physiotherapist 
prescribing would have positive effects on both clinical 
and cost-efficiencies for patients, clinicians and the health 
economy. Participants identified the positive impact on 
the overall patient journey as a potential benefit of NMP 
Figure 3 Likeliness to train as a prescriber: motivators and deterrents.
 o
n
 28 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024991 on 19 May 2019. Downloaded from 
8 Noblet TD, et al. BMJ Open 2019;9:e024991. doi:10.1136/bmjopen-2018-024991
Open access 
by reducing unnecessary appointments with general 
practitioners (GPs), specialists and surgeons. Specifically, 
participants recognised the current frequency of refer-
rals from physiotherapists to GPs for analgesic review, 
access to oxygen therapy, bronchodilators and antibiotics 
and ongoing pharmacological spasticity management. 
A common sentiment was that if physiotherapists could 
provide these services themselves, patients could have 
more timely access to appropriate medicines, which in 
turn would complement physiotherapeutic interventions 
and accelerate patient improvement/recovery. Partic-
ipants also anticipated that NMP could reduce acute 
injury recovery times and minimise the risk of chronicity, 
which in turn could reduce pressures on medical services 
and end costs to the consumer, Medicare and private 
health insurers. Furthermore, the presence of physiother-
apist prescribers in emergency departments and specialist 
multidisciplinary clinics was anticipated to reduce waiting 
times for patients, thus helping to meet performance 
measures set by governing bodies.
Access to prescription medicines
Seventy-one participants provided comments concerning 
potential improvements in accessing prescription medi-
cines for all Australians regardless of geographic or other 
socioeconomic factors. Specifically, it was suggested that 
physiotherapist prescribers in rural and remote regions 
could issue prescription medications to patients who might 
otherwise have limited access to medical professionals. 
However, no participants from rural/remote regions 
identified this theme within their responses. Participants 
from metropolitan and regional areas expressed concerns 
that patients in rural and remote regions may struggle 
to navigate an overburdened and expensive healthcare 
system, frequently waiting for weeks and travelling great 
distances to see their GP for medications such as anal-
gesics to supplement treatment from their physiothera-
pists. Participants from all locations identified potential 
benefits of NMP to healthcare consumers (regardless 
of location) whose principal healthcare practitioner is a 
physiotherapist, including persons with physical disabili-
ties and those involved in sports where acute injuries are 
managed pitch-side by the team physiotherapist.
Optimal therapeutics and clinical effectiveness
Fifteen participants reported the potential for improved 
optimisation of medicines in line with physical and 
psychosocial interventions and therefore enhanced 
clinical effectiveness. Participants stressed optimal and 
appropriate use of analgesics across all specialties, espe-
cially where adjustments (escalation or de-escalation) to 
prescriptions are required in line with physiotherapeutic 
intervention. It was felt that that the multimodal skills 
and techniques used by physiotherapists would promote a 
more integrated use of medicines into the overall patient 
management, with medicines forming just one part 
of a more comprehensive and coordinated approach. 
Participants specialising in women’s health echoed this T
ab
le
 2
 
P
er
ce
nt
ag
e 
of
 p
ar
tic
ip
an
ts
 fr
om
 d
iff
er
en
t 
he
al
th
 s
ec
to
rs
 a
nd
 g
eo
gr
ap
hi
ca
l l
oc
at
io
ns
, w
ho
 a
gr
ee
d
 w
ith
 t
he
 in
tr
od
uc
tio
n 
of
 p
hy
si
ot
he
ra
p
is
t 
p
re
sc
rib
in
g 
an
d
 a
re
 li
ke
ly
 
to
 t
ra
in
S
ur
ve
y 
it
em
Lo
ca
ti
o
n 
R
R
M
A
 %
 (9
5%
 C
I)
S
ub
g
ro
up
 c
o
m
p
ar
is
o
ns
 A
R
R
 %
 (9
5%
 C
I)
C
it
y
R
eg
io
na
l
R
em
o
te
C
it
y:
 r
eg
io
na
l
C
it
y:
 r
em
o
te
R
eg
io
na
l: 
re
m
o
te
A
gr
ee
d
 o
r 
st
ro
ng
ly
 a
gr
ee
d
 w
ith
 
au
to
no
m
ou
s 
p
re
sc
rib
in
g
80
.1
 (7
7.
3 
to
 8
3.
3)
76
.1
 (6
9.
0 
to
 8
1.
9)
56
.5
 (3
6.
8 
to
 7
4.
4)
4.
4 
(−
2.
2,
 1
2.
0)
24
.0
 (5
.8
 t
o 
43
.9
)*
19
.5
 (0
.4
 t
o 
40
.1
)*
Li
ke
ly
 t
o 
tr
ai
n 
as
 p
re
sc
rib
er
71
.9
 (6
8.
4 
to
 7
5.
2)
70
.9
 (6
3.
4 
to
 7
7.
3)
52
.2
 (3
3.
0 
to
 –
70
.8
)
1.
0 
(−
6.
3 
to
 9
.1
)
19
.8
 (0
.8
 t
o 
39
.2
)*
18
.7
 (−
1.
3 
to
 3
9)
S
ur
ve
y 
it
em
H
ea
lt
h 
se
ct
o
r 
%
 (9
5%
 C
I)
S
ub
g
ro
up
 c
o
m
p
ar
is
o
ns
 A
R
R
 %
 (9
5%
 C
I)
P
ri
va
te
P
ub
lic
O
th
er
P
ri
va
te
: p
ub
lic
P
ri
va
te
: o
th
er
P
ub
lic
: o
th
er
A
gr
ee
d
 o
r 
st
ro
ng
ly
 a
gr
ee
d
 w
ith
 
au
to
no
m
ou
s 
p
re
sc
rib
in
g
80
.7
 (7
6.
8 
to
 8
4.
1)
79
.0
 (7
4.
2 
to
 8
3.
1)
70
.8
 (6
1.
1 
to
 7
9.
0)
1.
7 
(−
4.
0 
to
 7
.6
)
9.
8 
(0
.8
 t
o 
20
.2
)*
8.
2 
(−
1.
3 
to
 1
8.
8)
Li
ke
ly
 t
o 
tr
ai
n
77
.4
 (7
3.
3 
to
 8
1.
1)
67
.5
 (6
2.
2 
to
 7
2.
5)
54
.2
 (4
4.
2 
to
 6
3.
8)
9.
9 
(3
.5
 t
o 
16
.4
)*
23
.3
 (1
2.
8 
to
 3
3.
8)
*
13
.4
 (2
.3
 t
o 
24
.5
)*
*S
ig
ni
fic
an
t 
at
 p
<
0.
05
.
A
R
R
, a
b
so
lu
te
 r
is
k 
re
d
uc
tio
ns
; R
R
M
A
, R
ur
al
, R
em
ot
e 
an
d
 M
et
ro
p
ol
ita
n 
A
re
as
.
 o
n
 28 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024991 on 19 May 2019. Downloaded from 
9Noblet TD, et al. BMJ Open 2019;9:e024991. doi:10.1136/bmjopen-2018-024991
Open access
Ta
b
le
 3
 
C
om
m
en
ts
 t
ha
t 
re
p
or
te
d
 o
r 
d
is
cu
ss
ed
 e
ac
h 
th
em
e 
an
d
 il
lu
st
ra
tiv
e 
q
uo
ta
tio
ns
 fr
om
 p
ar
tic
ip
an
ts
 (q
uo
ta
tio
ns
 h
av
e 
b
ee
n 
co
p
ie
d
 v
er
b
at
im
)
T
he
m
e
N
um
b
er
 o
f 
co
m
m
en
ts
 (n
)
Ill
us
tr
at
iv
e 
q
uo
ta
ti
o
ns
C
lin
ic
al
 a
nd
 c
os
t 
ef
fic
ie
nc
y
11
8
‘…
 [W
]o
ul
d
 b
en
efi
t 
p
eo
p
le
 fi
na
nc
ia
lly
 if
 t
he
y 
d
o 
no
t 
ha
ve
 t
o 
go
 b
ac
k 
to
 t
he
ir 
G
P
 fo
r 
m
ed
ic
at
io
n’
 (p
ar
tic
ip
an
t 
41
).
‘T
im
e 
an
d
 c
os
t 
sa
vi
ng
s 
fo
r 
b
us
y 
w
or
ke
rs
, t
ha
t 
is
, n
ot
 h
av
in
g 
to
 g
o 
to
 2
 a
p
p
oi
nt
m
en
ts
’ (
p
ar
tic
ip
an
t 
12
7)
.
‘…
[I]
m
p
ro
ve
 p
at
ie
nt
 fl
ow
 a
nd
 d
ec
re
as
e 
re
lia
nc
e 
on
 m
ed
ic
al
 s
ta
ff
’ (
p
ar
tic
ip
an
t 
49
0)
.
‘W
or
ki
ng
 in
 a
n 
E
m
er
ge
nc
y 
D
ep
t 
w
he
re
 a
cc
es
s 
an
d
 fl
ow
 is
 c
rit
ic
al
, e
na
b
lin
g 
ad
va
nc
ed
 m
us
c 
[m
us
cu
lo
sk
el
et
al
] p
hy
si
os
 t
o 
p
re
sc
rib
e 
w
ou
ld
 im
p
ro
ve
 e
ffi
ci
en
cy
 in
 t
he
 w
or
kp
la
ce
 a
nd
 t
he
 p
at
ie
nt
 e
xp
er
ie
nc
e’
 (p
ar
tic
ip
an
t 
7)
.
‘T
he
 a
b
ili
ty
 t
o 
p
re
sc
rib
e 
w
ou
ld
 e
na
b
le
 m
or
e 
ef
fic
ie
nt
 s
er
vi
ce
 d
el
iv
er
y 
to
 p
at
ie
nt
s.
 A
 lo
t 
of
 t
im
e 
is
 w
as
te
d
 b
ac
k 
an
d
 fo
rt
h 
tr
yi
ng
 t
o 
ge
t 
ap
p
ro
p
ria
te
 p
ai
n 
m
ed
ic
at
io
n,
 a
nt
ib
io
tic
s 
et
c 
in
 a
 t
im
el
y 
fa
sh
io
n’
 (p
ar
tic
ip
an
t 
32
).
A
cc
es
s 
to
 
p
re
sc
rip
tio
n 
m
ed
ic
in
es
71
‘W
or
ki
ng
 in
 a
 r
ur
al
 a
re
a 
w
he
re
 it
 is
 d
iffi
cu
lt 
fo
r 
a 
p
at
ie
nt
 t
o 
b
e 
ab
le
 t
o 
m
ak
e 
a 
G
P
 a
p
p
oi
nt
m
en
t 
(ty
p
ic
al
 2
–3
 w
ee
k 
w
ai
t) 
I c
an
 s
ee
 t
he
 
b
en
efi
t 
of
 s
tr
ea
m
lin
in
g 
th
e 
sy
st
em
 b
y 
gi
vi
ng
 p
re
sc
rib
in
g 
rig
ht
s 
to
 p
hy
si
os
 w
ho
 a
re
 a
ls
o 
p
rim
ar
y 
ca
re
 p
ro
fe
ss
io
na
ls
’ (
p
ar
tic
ip
an
t 
63
0)
.
‘W
ill
 r
ed
uc
e 
b
ur
d
en
 o
n 
ov
er
b
oo
ke
d
 G
P
’s
 a
nd
 E
D
’s
 fo
r 
p
eo
p
le
 w
ith
 p
ai
n 
p
ro
b
le
m
s,
 t
ha
t 
is
, S
ev
er
e 
A
cu
te
 L
ow
 b
ac
k 
(p
ai
n)
 o
r 
th
os
e 
w
ith
 in
fla
m
m
at
or
y 
in
ju
rie
s’
 (p
ar
tic
ip
an
t 
87
3)
.
‘P
hy
si
ot
he
ra
p
is
ts
 w
or
ki
ng
 in
 p
ub
lic
 h
ea
lth
 h
el
p
 p
eo
p
le
 fr
om
 d
iff
er
en
t 
m
in
or
ity
 g
ro
up
s 
ev
er
y 
d
ay
 -
 in
d
ig
en
ou
s,
 r
ec
en
t 
im
m
ig
ra
nt
s,
 
p
eo
p
le
 r
el
yi
ng
 o
n 
d
is
ab
ili
ty
 p
en
si
on
s,
 e
tc
. G
re
at
er
 a
cc
es
s 
to
 s
im
p
le
 m
ed
ic
at
io
ns
 w
ou
ld
 im
p
ro
ve
 t
he
ir 
q
ua
lit
y 
of
 li
fe
 a
nd
 r
ed
uc
e 
un
ne
ce
ss
ar
y 
at
te
nd
an
ce
s 
at
 o
ve
r-
 w
or
ke
d
 G
P
 c
lin
ic
s’
 (p
ar
tic
ip
an
t 
12
).
‘I 
w
or
k 
in
 a
 c
ou
nt
ry
 s
et
tin
g 
w
he
re
 t
ra
ve
l t
im
es
 a
re
 s
ig
ni
fic
an
t 
an
d
 it
 c
an
 b
e 
d
iffi
cu
lt 
to
 g
et
 a
 d
oc
to
r’s
 a
p
p
oi
nt
m
en
t 
an
d
, w
he
n 
in
ju
re
d
 
or
 w
ith
ou
t 
a 
lic
en
ce
, p
at
ie
nt
s 
re
ly
 o
n 
fr
ie
nd
s,
 r
el
at
iv
es
 o
r 
p
ub
lic
 t
ra
ns
p
or
t 
to
 r
ea
ch
 a
p
p
oi
nt
m
en
ts
. T
hi
s 
m
ea
ns
 t
ha
t 
a 
p
hy
si
ot
he
ra
p
y 
ap
p
oi
nt
m
en
t 
w
ith
 p
re
sc
rip
tio
n 
w
ou
ld
 b
ec
om
e 
a 
m
or
e 
ef
fic
ie
nt
 u
se
 o
f t
im
e 
an
d
 p
eo
p
le
 a
re
 m
or
e 
lik
el
y 
to
 c
om
p
ly
’ (
p
ar
tic
ip
an
t 
65
4)
.
O
p
tim
al
 t
he
ra
p
eu
tic
s 
an
d
 c
lin
ic
al
 
ef
fe
ct
iv
en
es
s
15
‘W
ill
 a
llo
w
 p
hy
si
ot
he
ra
p
is
t 
to
 a
d
ju
st
 m
ed
ic
at
io
ns
 p
ar
tic
ul
ar
ly
 in
 m
an
ag
em
en
t 
of
 c
hr
on
ic
 p
ai
n 
an
d
 L
B
P
…
’ (
p
ar
tic
ip
an
t 
33
3)
.
‘T
he
re
 is
 c
on
si
d
er
ab
le
 p
ot
en
tia
l f
or
 t
hi
s 
to
 s
ig
ni
fic
an
tly
 im
p
ro
ve
 a
d
he
re
nc
e 
to
 m
ed
ic
at
io
n 
re
gi
m
es
 a
nd
 t
o 
p
ro
b
le
m
 s
ol
ve
 in
 a
 t
im
e 
ap
p
ro
p
ria
te
 m
an
ne
r’
 (p
ar
tic
ip
an
t 
45
).
‘P
hy
si
os
 t
en
d
 t
o 
sp
en
d
 m
or
e 
tim
e 
w
ith
 p
at
ie
nt
s 
an
d
 o
ft
en
 a
re
 b
et
te
r 
sk
ill
ed
 t
o 
re
co
m
m
en
d
 m
ed
ic
at
io
ns
 t
ha
n 
ev
en
 t
he
 r
eg
is
tr
ar
s,
 
es
p
ec
ia
lly
 in
 m
y 
ur
og
yn
ae
 a
d
va
nc
ed
 p
ra
ct
ic
e 
cl
in
ic
s,
 b
ei
ng
 a
b
le
 t
o 
p
re
sc
rib
e 
an
tic
ho
lin
er
gi
cs
 a
nd
 v
ag
in
al
 o
es
tr
og
en
s 
w
ou
ld
 
si
gn
ifi
ca
nt
ly
 in
cr
ea
se
 t
he
 e
ffi
ci
en
cy
 o
f t
he
 c
lin
ic
s 
as
 c
ur
re
nt
ly
 [p
at
ie
nt
s]
 n
ee
d
 t
w
o 
ap
p
oi
nt
m
en
t 
tim
es
 fo
r 
th
is
’ (
p
ar
tic
ip
an
t 
27
6)
.
…
‘[D
]e
-p
re
sc
rib
in
g’
 c
ou
ld
 p
ot
en
tia
lly
 b
e 
a 
ve
ry
 im
p
or
ta
nt
 r
ol
e 
fo
r 
P
hy
si
os
’ (
p
ar
tic
ip
an
t 
79
0)
.
Ti
m
e 
m
an
ag
em
en
t
9
‘T
he
 t
im
e 
re
q
ui
re
d
 t
o 
ke
ep
 u
p
 t
o 
d
at
e 
w
ith
 m
ed
ic
at
io
ns
 a
nd
 w
el
l a
s 
p
hy
si
ot
he
ra
p
y 
sk
ill
s 
to
 b
e 
sa
fe
 a
nd
 e
ffe
ct
iv
e 
I f
ee
l w
ou
ld
 im
p
ac
t 
th
e 
tim
e 
av
ai
la
b
le
 t
o 
tr
ea
t 
p
at
ie
nt
s…
’ (
p
ar
tic
ip
an
t 
24
6)
.
‘P
ut
s 
ex
tr
a 
p
re
ss
ur
e 
on
 a
p
p
oi
nt
m
en
t 
tim
e 
w
he
n 
w
e 
al
re
ad
y 
ha
ve
 t
o 
d
ea
l w
ith
 fu
ll 
as
se
ss
m
en
t 
an
d
 t
re
at
m
en
t 
of
 t
he
 p
at
ie
nt
’s
 
p
hy
si
ca
l a
nd
 p
sy
ch
o-
so
ci
al
 n
ee
d
s’
 (p
ar
tic
ip
an
t 
69
3)
.
 o
n
 28 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024991 on 19 May 2019. Downloaded from 
10 Noblet TD, et al. BMJ Open 2019;9:e024991. doi:10.1136/bmjopen-2018-024991
Open access 
statement highlighting the appropriate use of anticho-
linergics and vaginal oestrogens necessary to holistically 
treat many of their patients.
Participants agreed that the close working relation-
ships between physiotherapists and their patients, due 
to the comprehensive time spent completing physiother-
apeutic interventions may be used to promote patients’ 
compliance to their prescribed medicines. Physiothera-
pist prescribers with the appropriate knowledge and skills 
could legally reinforce the appropriate use of medicines, 
better recognising poor adherence, dependency, abuse or 
adverse side effects masquerading as conditions treated 
by physiotherapists.
time management
Nine participants suggested that the time requirements 
needed to train as a physiotherapist prescriber and 
ongoing time required for continuous professional devel-
opment (CPD) may be prohibitive to introducing NMP 
in Australia.
Likely, time away from clinical work for education 
and development and NMP duties were seen to poten-
tially interfere with tasks currently performed by clini-
cians. Furthermore, participants felt that although 
greater efficiency and access to medicines may benefit 
heath consumers, time presently spent treating patients 
in the current scope of practice would be lost to proce-
dures related to prescribing medicines. In other words, 
although NMP may decrease medical practitioners’ work-
load, this would instead increase pressures on already 
understaffed physiotherapy departments and possibly 
even threaten clinical outcomes.
Further insights
The final question allowed participants to express any 
additional thoughts and views about physiotherapist 
prescribing that they deemed important and had not 
already been captured. Two hundred and sixty-six partic-
ipants provided comments. Three major themes were 
identified:
1. Quality and safety: clinical governance, policies and 
procedures and education.
2. Professional issues.
3. Physiotherapy professional priorities.
Table 4 lists the number of comments that discussed 
each theme and subtheme, providing Illustrative quota-
tions from participants.
Quality and safety
Two hundred and seventeen comments were received 
regarding quality and safety concerns around NMP. These 
focused on clinical governance, policies and procedures 
and educational requirements for prescribers.
One hundred and forty-four participants proposed 
that adequate clinical governance, policies and proce-
dures should be in place for physiotherapist NMP to 
be successful. Participants identified the need for a 
clear scope of practice linked to a physiotherapy-centric 
formulary that is endorsed and regulated promoting 
transparency and safety. Participants raised concerns that 
statutory processes and procedures defining a limited 
formulary could quickly become outdated due to medical 
advances. Meanwhile, other participants identified that a 
limited formulary based around the profession’s specialist 
areas of practice would be safest, protecting clinicians 
from pressures to prescribe out of scope. Participants 
were concerned that unless communication channels 
were maintained between physiotherapist prescribers and 
GPs, there is a risk that patients could shop around for 
prescriptions, potentially aiding the abuse of prescription 
medication and causing clinical incidents. Participants 
were also concerned that the increase in professional 
risk due to physiotherapist prescribing would lead to an 
increase in indemnity insurance premiums.
Seventy-three comments were received with regards to 
education. Participants recognised that the scope of prac-
tice must be absolutely clear, endorsed and underpinned 
by a robust clinical education framework. They felt that 
thought must be given to the process of assessment and 
selection of appropriately qualified assessors from outside 
the profession including medical doctors and pharmacists 
to ensure quality and safe practice among prescribers.
Access to prescribing courses for physiotherapists 
living in regional and remote areas was highlighted as a 
potential issue due to the distance to the nearest univer-
sity. Participants recommended that the regulatory body 
should dictate compulsory annual CPD hours, and peri-
odic reassessment of competency should be mandatory. 
Participants had varying opinions with regards to when 
physiotherapists should be able to train and qualify as 
prescribers; however, the participants agreed that current 
preregistration physiotherapy programmes should be 
updated to include pharmacology and therapeutics on 
their syllabi in preparation for the future.
Professional issues
Thirty-nine participants provided comments on important 
professional issues. Participants noted that the introduc-
tion of physiotherapist prescribing could change the 
‘physiotherapy brand’, weakening the public’s percep-
tion of physiotherapists as experts in manual therapy and 
exercise, leading to potential loss of patients to other 
emerging healthcare professions. It was suggested that a 
marketing campaign may be necessary to manage public 
expectation and minimise consumer confusion.
Interprofessional relationships between physiother-
apists, medical practitioners and pharmacists were 
highlighted as being fragile. Participants warned that 
members of the Australian Medical Association would not 
support the introduction of physiotherapist prescribing, 
alluding to the possibility that medical doctors might see 
the introduction as a direct challenge to their authority 
and private businesses, leading them to reduce referrals 
to physiotherapy. Participants specifically identified the 
impact this may have on practice revenues in the musculo-
skeletal and sport specialties. That said, other participants 
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reported great support from medical colleagues and the 
greater multidisciplinary team, citing the streamlining 
of current clinical services and patient pathways, along-
side improved access medicines as key reasons for posi-
tive interprofessional support. Participants warned that 
although these efficiencies would reduce service costs, 
establishing physiotherapist prescribing would require 
an initial coordinated investment to ensure appropriate 
governance, clinical education and safe/quality imple-
mentation across Australia.
Physiotherapy professional priorities
Forty participants commented on the profession’s profes-
sional priorities. Participants described the risks of junior 
physiotherapists underdeveloping their traditional phys-
iotherapy skills used to treat impairments and instead 
depending on medicines. To mitigate these risks, a 
robust career progression framework would need to be 
introduced to ensure ongoing high-level professional 
development across all specialties. To safeguard the good 
reputation of the profession, participants focused on 
maintenance of quality and safety for patients and clini-
cians. Physiotherapist prescribing should be introduced 
in a structured and organised manner with all physio-
therapists supporting each other, even if they do not wish 
to prescribe themselves. Furthermore, participants also 
commented that the ability for physiotherapists to directly 
refer to specialist medical or surgical practitioners and 
ensuring appropriate patient rebates for imaging would 
have a positive clinical impact.
DisCussiOn
This is the first study to explore the perceptions of Austra-
lian physiotherapists regarding NMP by physiotherapists 
in Australia. The majority of physiotherapists agreed that 
autonomous prescribing responsibilities should be intro-
duced for physiotherapists in Australia. Improvements 
in the efficiency of healthcare delivery, access to medi-
cines and reductions in costs across the health economy 
were suggested as potential benefits. These findings 
concur with those reported by student physiotherapists 
in Australia as detailed in a related article,16 as well as 
reflecting an evaluation of physiotherapist and podia-
trist independent prescribers in the UK,27 strengthening 
the external validity and transferability of the results. 
Concerns regarding clinical safety and management of 
clinical risk were clearly identified throughout the quan-
titative and qualitative sections of the survey, supporting 
the results of an international multiprofession mixed-
methods systematic review investigating the barriers and 
facilitators of the implementation and utilisation of NMP.5 
The systematic review identified the need to address 
governance, safety, educational and financial factors 
prior to training prescribers to protect both patients and 
clinicians from poor practice, process and clinical path-
ways.5 To safely and effectively introduce physiotherapist 
prescribing, politicians, regulatory bodies, healthcare 
managers, clinicians and the APA, in consultation with 
experts and health consumers, must develop robust legis-
lation, regulation, clinical governance and safety policies 
as well as well-defined education and career frameworks.
To ensure that physiotherapists are equipped to 
prescribe safely within a multimodal physiotherapeutic 
context, participants perceived that a contemporary, 
innovative and robust educational framework should 
be developed prior to the introduction of physiothera-
pist prescribing. This perception reflects contemporary 
educational literature that urges educators to care-
fully consider the ever-evolving healthcare system when 
designing curricula for physiotherapists.28 Transforming 
healthcare needs will require the next generation of phys-
iotherapists to be ready to adapt to changes in consumer 
complexity and expectation, working within new models 
of care that are organised, funded and delivered in inno-
vative ways. It has been postulated in the literature that a 
more flexible, broader and deeper clinical expertise will 
be required by physiotherapists if the Australian physio-
therapy profession wishes to succeed as evidence-based 
and viable health providers in the integrated, value-driven 
health industry of the future.29
To guarantee quality development of physiotherapists 
across the profession, participants called for the creation 
of a contemporary career development framework into 
which prescribing would be integrated to safeguard 
mastery of traditional skills, govern quality practice and 
maintain the ‘physiotherapy brand’. This appeal concurs 
with literature reporting that career frameworks within 
healthcare help the public understand different clini-
cians’ knowledge, skills and roles within one profession, as 
well as providing purpose and direction for professionals, 
promoting engagement and job satisfaction.30 31 Further, 
academic qualifications and increased clinical respon-
sibility should lead to enhanced remuneration if phys-
iotherapists are to adopt prescribing into their clinical 
practice, as a lack of remuneration has been recognised 
as a barrier to NMP across other professions.32–34 Improve-
ments in recruitment and retention within the profession 
were anticipated due to improvements in job satisfaction 
for clinicians and greater recognition and professional 
reputation, echoing the findings of other NMP profes-
sions reported in the literature.32 35 36
Physiotherapists working in cities and regional areas 
were consistent in observing that physiotherapist 
prescribing would improve access to medicines across 
all regions but would be specifically helpful in rural/
remote areas where access to medical prescribers may be 
limited. However, physiotherapists from rural/remote 
areas, although positive about the introduction of phys-
iotherapist prescribing, were less likely to wish to train 
as prescribers, identifying potential increased risks when 
working in geographical isolation owing to a lack of 
clinical support. Due to a perceived lack of need in the 
present healthcare environment, participants felt that 
not all physiotherapists would benefit from undertaking 
a NMP course. Those working in close multidisciplinary 
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teams with colocated prescribers, or those employed 
in non-clinical roles such as healthcare managers or 
academic physiotherapists were found to be less likely 
to wish to become prescribers than clinicians working 
in the public and private sectors. There was debate as to 
when and who should undertake the training, with no 
consistency as to whether education should be included 
in foundation level courses or become a postregistration 
qualification for those with a specified clinical experi-
ence. Furthermore, rural physiotherapists identified that 
the distance to universities may act as a barrier to training 
as a prescriber, highlighting the need for educators to 
consider flexible learning methods such as online educa-
tion and video teleconferencing to fulfil the academic 
requirements of a NMP course. It is therefore impera-
tive that a robust, fit for purpose, transparent and future 
proof education framework is developed to ensure unity 
within the Australian physiotherapy profession and assur-
ance for all stakeholders that physiotherapists prescribers 
would be adequately prepared for practice.
Participants’ perceptions that physiotherapist 
prescribing in Australia would reduce costs to their 
patients, healthcare services and to the health economy as 
a whole is supported by an economic review commissioned 
by the APA. The report predicts savings to the Australian 
health economy of over $9.22 million per year if physio-
therapist prescribing was implemented37; however, this is 
not currently reflected in the health economics literature. 
A robust low risk of bias systematic review investigating 
the clinical and cost-effectiveness of NMP found only one 
inadequately powered pilot randomised controlled trial 
investigating clinical effectiveness to date, concluding 
that the benefit of NMP to the health economy remains 
unclear.4 This gap in the literature highlights the need 
for robust, adequately powered economic evaluation to 
investigate the cost–benefits perceived by physiothera-
pists across Australia.
strengths and limitations
This is the first study investigating the perceptions of 
AHPRA-registered physiotherapists about the potential 
introduction of NMP among physiotherapists in Australia, 
and so, alongside the data from student physiotherapists 
presented in the related article, provides an important over-
view of the current associated professional landscape. The 
data should be used to guide the APA, health departments 
and political leaders towards successful implementation of 
physiotherapist prescribing in Australia. As with all survey-
based research, limitations are inherent due to selection 
and response bias. The survey was anonymous, so partici-
pants may have biased the results by completing the online 
questionnaire multiple times. Furthermore, physiotherapists 
with strong views or vested interests may be more likely to 
complete the questionnaire, meaning that their answers may 
not reflect the views of the wider profession.
A representative survey response rate (as per precur-
sory power calculations) was achieved.13 Although only 
3% of AHPRA responded, this reflected the response rate 
of a previous national evaluation of physiotherapists,37 
where similarly, it was not possible to contact all regis-
tered physiotherapists directly due to the AHPRA privacy 
policy. Physiotherapists who were not APA members at 
the time of the survey would have been unaware of the 
questionnaire unless they were provided with a link to 
the questionnaire through professional networks. It is 
impossible to determine why 97% of AHPRA registered 
physiotherapists did not participate; therefore, the risk of 
bias remains unknown and should be considered when 
interpreting the results. In line with recent Australian 
regulatory data,38 the sample was representative of all 
registered physiotherapists in Australia in terms of age, 
gender and state in which they practise. Unfortunately, 
no national demographic data exist demonstrating the 
geographic location or health sector of registered phys-
iotherapists’ employment. It is therefore likely that the 
comparable demographic profile of the study’s sample to 
contemporary national evaluations enhances generalis-
ability of the data to the greater physiotherapist popula-
tion in Australia and reduces risk of bias.
COnClusiOn
AHPRA-registered physiotherapists perceive that the 
introduction of autonomous physiotherapist prescribing 
would be beneficial for the Australian population and 
should be introduced. Acceptance of physiotherapist 
prescribing and the likelihood of physiotherapists to 
train as prescribers vary depending on location and the 
health sector in which a physiotherapist works. Legisla-
tion, regulation and governance around the use of phys-
iotherapist prescribing all require careful consideration 
and consultation with experts and health consumers to 
ensure the safety and quality demanded by physiotherapy 
profession. Rigorous national educational frameworks 
should be developed within a transparent career devel-
opment structure to ensure prescribing is used within a 
multimodal physiotherapeutic context, safeguarding the 
professional reputation of physiotherapy.
It is recommended that the APA, health departments and 
political leaders use the results of this study in conjunction 
with cost–benefit analyses, risk analysis as well as assessment 
of the health requirements and consultation with key stake-
holders to redefine the scope of Australian physiotherapy 
to include NMP. Future research is required to investigate 
the concerns raised by participants. It would be valuable to 
interview current physiotherapist prescribers to interrogate 
the perceived benefits and concerns about physiotherapy 
prescribing identified by the Australian physiotherapists. 
Lessons learnt in the UK could thus be used to inform imple-
mentation internationally.
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